FB
Fidelity Biosciences
Cambridge, Massachusetts, United States
Fidelity Biosciences merged with Devonshire Investors' technology venture capital fund in October 2015 to become F-Prime Capital. F-Prime Capital is a global venture capital firm that invests in life sciences, healthcare, and technology companies, with a focus on innovative early-stage companies.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (50% of deals). Average disclosed round size is $113.8M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series C
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Denali Therapeutics Inc. | Series D | $217M | May 2015 |
| Denali Therapeutics Inc. | Unknown | $88M | May 2015 |
 Innovent Biologics, Inc. | Series C | $100M | Jan 2015 |
 Blueprint Medicines | Series C | $50M | Nov 2014 |
Top Co-Investors
ARCH Venture Partners2 shared
Flagship Ventures2 shared
Alaska Permanent Fund2 shared
RA Capital Management1 shared
Perceptive Advisors1 shared
Redmile Group1 shared
Casdin Capital1 shared
Nextech Invest1 shared
Third Rock Ventures1 shared
Temasek Holdings1 shared
Legend Capital1 shared
Lilly Asia Ventures1 shared
Last updated: 16 April 2026